The most druggable targets in neurodegeneration are not the ones we expected—axonal protection beats regeneration for now

We have spent decades hunting for drugs that regrow axons in ALS, Parkinson, and spinal cord injury. PTEN inhibition, RhoA blockers, LINGO-1 antibodies—all promising in rodents, none delivering in humans. Meanwhile, quietly advancing through clinical trials are a different class: drugs that protect what is still there. The paradigm is shifting from regeneration to preservation.